Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/7/25 16:43 | 3/5/25 | PCVX | Health | BioPrd | Biological Products, (No Diag | Eydelman Mikhail | CA | O | SVP,GC,C | 13 | S.d | -4,176 | 91.77 | 0 | -46 | 42 | D | |||||||||||||||
3/3/25 21:14 | 3/3/25 | PCVX | Health | BioPrd | Biological Products, (No Diag | Wassil Jim | CA | O | COO | 13 | S.d | -7,799 | 93.96 | 0 | -83 | 218 | D | |||||||||||||||
2/19/25 18:04 | 2/18/25 | PCVX | Health | BioPrd | Biological Products, (No Diag | Guggenhime Andrew | CA | O | P,CFO | 12 | S.d | -12,029 | 92.53 | 0 | -130 | 109 | D | |||||||||||||||
1/17/25 16:05 | 1/15/25 | PCVX | Health | BioPrd | Biological Products, (No Diag | Loxam Teri | CA | D | 2 | S.d | -1,259 | 100.70 | 0 | -13 | 7 | D | ||||||||||||||||
12/10/24 16:10 | 12/9/24 | PCVX | Health | BioPrd | Biological Products, (No Diag | Pickering Grant | CA | DO | CEO | 16 | S.d | -16,958 | 91.71 | 0 | -185 | 775 | I | |||||||||||||||
9/5/24 17:15 | 9/3/24 | PCVX | Health | BioPrd | Biological Products, (No Diag | Cowan Elvia | CA | O | SVP,Fina | 3 | S.d | -1,363 | 90.89 | 0 | -15 | 13 | D | |||||||||||||||
6/5/24 16:59 | 6/3/24 | PCVX | Health | BioPrd | Biological Products, (No Diag | Gilbert Halley E | CA | D | 1 | S.d | -1,329 | 73.00 | 0 | -18 | 6 | D |
D | Derivative transaction in filing (usually option exercise) |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
A | Amended filing |
E | Error detected in filing |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |